Most cited papers from Lytix Biopharma (Norway)

Lytix Biopharma (Norway)

What are the most cited papers from Lytix Biopharma (Norway)?

The most cited paper from Lytix Biopharma (Norway) is "Consensus guidelines for the definition, detection and interpretation of immunogenic cell death" (Lorenzo Galluzzi et al., 2020), with 1,116 citations. Next come "Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)" (216) and "A Synthetic Antimicrobial Peptidomimetic (LTX 109): Stereochemical Impact on Membrane Disruption" (170).

Published TypeFieldAccessCitations

Showing 50 of 61 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death Lorenzo Galluzzi et al. · Journal for ImmunoTherapy of Cancer Open access	Mar 2020	1,116
2	Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT) Aurélien Marabelle et al. · Annals of Oncology Open access	6 Oct 2018	216
3	A Synthetic Antimicrobial Peptidomimetic (LTX 109): Stereochemical Impact on Membrane Disruption Johan Mattias Isaksson, Bjørn Olav Brandsdal, Magnus Engqvist et al. · Journal of Medicinal Chemistry	6 Jul 2011	170
4	Use of the Capripoxvirus homologue of Vaccinia virus 30kDa RNA polymerase subunit (RPO30) gene as a novel diagnostic and genotyping target: Development of a classical PCR method to differentiate Goat poxvirus from Sheep poxvirus Charles Euloge Lamien, Christian Le Goff, Roland Silber et al. · Veterinary Microbiology	18 Oct 2010	168
5	Synthetic Antimicrobial Peptidomimetics with Therapeutic Potential Bengt Erik Haug, Wenche Stensen, Manar Kalaaji et al. · Journal of Medicinal Chemistry	21 Jun 2008	161
6	Antimicrobial Peptides with Stability toward Tryptic Degradation Johan Svenson, Wenche Stensen, Bjørn Olav Brandsdal et al. · Biochemistry	29 Feb 2008	143
7	The oncolytic peptide LTX-315 triggers immunogenic cell death Heng Zhou, Sabrina Forveille, Allan Sauvat et al. · Cell Death and Disease Open access	10 Mar 2016	139
8	Albumin Binding of Short Cationic Antimicrobial Micropeptides and Its Influence on the in Vitro Bactericidal Effect Johan Svenson, Bjørn Olav Brandsdal, Wenche Stensen et al. · Journal of Medicinal Chemistry	15 Jun 2007	137
9	Photodynamic therapy with redaporfin targets the endoplasmic reticulum and Golgi apparatus Lígia Catarina Gomes-da-Silva, Liwei Zhao, Lucillia Bezu et al. · The EMBO Journal Open access	28 May 2018	117
10	LTX-109 Is a Novel Agent for Nasal Decolonization of Methicillin-Resistant and -Sensitive Staphylococcus aureus Anna C. Nilsson, Håkan Janson, Hedda Wold et al. · Antimicrobial Agents and Chemotherapy Open access	21 Oct 2014	102
11	Antifouling Compounds from the Sub-Arctic Ascidian Synoicum pulmonaria: Synoxazolidinones A and C, Pulmonarins A and B, and Synthetic Analogues Rozenn Trépos, Gunnar Cervin, Claire Hellio et al. · Journal of Natural Products	2 Sep 2014	101
12	The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade Takahiro Yamazaki, Jonathan M. Pitt, Marie Vétizou et al. · Cell Death and Differentiation Open access	15 Apr 2016	96
13	High in vitro antimicrobial activity of synthetic antimicrobial peptidomimetics against staphylococcal biofilms Kerry Flemming, Claus Klingenberg, Jorunn Pauline Cavanagh et al. · Journal of Antimicrobial Chemotherapy	18 Oct 2008	92
14	Bulky Nonproteinogenic Amino Acids Permit the Design of Very Small and Effective Cationic Antibacterial Peptides Bengt Erik Haug, Wenche Stensen, Trine Stiberg et al. · Journal of Medicinal Chemistry	16 Jul 2004	90
15	LTX-315: A First-In-Class Oncolytic Peptide that Reprograms the Tumor Microenvironment Baldur Sveinbj⊘rnsson, Ketil André Camilio, Bengt Erik Haug et al. · Future Medicinal Chemistry Open access	11 May 2017	87
16	Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315 Ketil André Camilio, Gerd Marit Berge, Chandra Sekhar Ravuri et al. · Cancer Immunology Immunotherapy Open access	27 Mar 2014	82
17	Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors James F. Spicer et al. · Clinical Cancer Research Open access	4 Feb 2021	81
18	Targeting Cancer Heterogeneity with Immune Responses Driven by Oncolytic Peptides Ilio Vitale, Takahiro Yamazaki, Erik Wennerberg et al. · Trends in cancer ReviewOpen access	14 Jan 2021	76
19	In Vitro Activities of LTX-109, a Synthetic Antimicrobial Peptide, against Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, Daptomycin-Nonsusceptible, and Linezolid-Nonsusceptible Staphylococcus aureus Louis Donald Saravolatz, Joan Pawlak, Leonard Johnson et al. · Antimicrobial Agents and Chemotherapy Open access	15 May 2012	76
20	Determining the Absolute Configuration of Two Marine Compounds Using Vibrational Chiroptical Spectroscopy Kathrin H. Hopmann, Jaroslav Šebestı́k, Jana Novotná et al. · The Journal of Organic Chemistry	12 Dec 2011	75
21	The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells Liv-Marie Eike, Nannan Yang, Øystein Rekdal et al. · Oncotarget Open access	13 Oct 2015	71
22	Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide Gerd Marit Berge, Liv Tone Eliassen, Ketil André Camilio et al. · Cancer Immunology Immunotherapy Open access	26 Apr 2010	70
23	Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model Ketil André Camilio, Mengyu Wang, Brynjar Mauseth et al. · Breast Cancer Research Open access	22 Jan 2019	66
24	Determination of Absolute Configuration and Conformation of a Cyclic Dipeptide by NMR and Chiral Spectroscopic Methods Xiaojun Li, Kathrin H. Hopmann, Jana Hudecová et al. · The Journal of Physical Chemistry A	24 Jan 2013	64
25	LTX-315 (Oncopore™) Ketil André Camilio, Øystein Rekdal, Baldur Sveinbjørnsson · OncoImmunology Open access	Jun 2014	61
26	The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells Bodil Fadnes, Øystein Rekdal, Lars Uhlin‐Hansen · BMC Cancer Open access	15 Jun 2009	58
27	The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization Heng Zhou, Sabrina Forveille, Allan Sauvat et al. · Oncotarget Open access	10 Sep 2015	57
28	Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model Janne M. Nestvold, Mengyu Wang, Ketil André Camilio et al. · OncoImmunology Open access	16 Jun 2017	54
29	Ionizing radiation abrogates the pro-tumorigenic capacity of cancer-associated fibroblasts co-implanted in xenografts Maria Tunset Grinde, Jørg Vik, Ketil André Camilio et al. · Scientific Reports Open access	25 Apr 2017	53
30	Relative Spatial Positions of Tryptophan and Cationic Residues in Helical Membrane-active Peptides Determine Their Cytotoxicity Øystein Rekdal, Bengt Erik Haug, Manar Kalaaji et al. · Journal of Biological Chemistry Open access	5 Nov 2011	51
31	Application of the Suzuki–Miyaura cross-coupling to increase antimicrobial potency generates promising novel antibacterials Bengt Erik Haug, Wenche Stensen, John S. M. Svendsen · Bioorganic & Medicinal Chemistry Letters	22 Dec 2006	45
32	LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma Morten Nielsen, Tine Juul Monberg, Vibeke Sundvold et al. · OncoImmunology Open access	7 Dec 2023	44
33	LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells Takahiro Yamazaki, Erik Wennerberg, Michal Hensler et al. · OncoImmunology Open access	2021	44
34	Small lytic peptides escape the inhibitory effect of heparan sulfate on the surface of cancer cells Bodil Fadnes, Lars Uhlin‐Hansen, Inger Lindin et al. · BMC Cancer Open access	31 Mar 2011	44
35	Tumor lysis with LTX-401 creates anticancer immunity Wei Xie, Laura Mondragón, Brynjar Mauseth et al. · OncoImmunology Open access	13 Apr 2019	42
36	The oncolytic compound LTX-401 targets the Golgi apparatus Heng Zhou, Allan Sauvat, Lígia Catarina Gomes-da-Silva et al. · Cell Death and Differentiation Open access	2 Sep 2016	41
37	The oncolytic peptide LTX-315 triggers necrotic cell death Sabrina Forveille, Heng Zhou, Allan Sauvat et al. · Cell Cycle Open access	2 Nov 2015	39
38	In Vitro Characterization of Human Peptide Transporter hPEPT1 Interactions and Passive Permeation Studies of Short Cationic Antimicrobial Peptides Gøril Eide Flaten, Gábor Kottra, Wenche Stensen et al. · Journal of Medicinal Chemistry Open access	14 Mar 2011	38
39	Absolute Configuration of a Cyclic Dipeptide Reflected in Vibrational Optical Activity: Ab Initio and Experimental Investigation Xiaojun Li, Kathrin H. Hopmann, Jana Hudecová et al. · The Journal of Physical Chemistry A	15 Feb 2012	34
40	Time-Domain Analysis of Molecular Dynamics Trajectories Using Deep Neural Networks: Application to Activity Ranking of Tankyrase Inhibitors Vladimir P. Berishvili, Valentin O. Perkin, Andrew E. Voronkov et al. · Journal of Chemical Information and Modeling	5 Jul 2019	31
41	Machine Learning Classification Models to Improve the Docking‐based Screening: A Case of PI3K‐Tankyrase Inhibitors Vladimir P. Berishvili, Andrew E. Voronkov, Eugene V. Radchenko et al. · Molecular Informatics	14 Jun 2018	31
42	LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects Hsin-Wei Liao, Christopher Garris, Christina Pfirschke et al. · Cell Stress Open access	8 Nov 2019	30
43	Short Cationic Antimicrobial Peptides Display Superior Antifungal Activities toward Candidiasis and Onychomycosis in Comparison with Terbinafine and Amorolfine Wenche Stensen, R. S. Turner, Marc B. Brown et al. · Molecular Pharmaceutics	31 Aug 2016	29
44	Recruitment of LC3 to damaged Golgi apparatus Lígia Catarina Gomes-da-Silva, Ana Joaquina Jiménez, Allan Sauvat et al. · Cell Death and Differentiation Open access	22 Oct 2018	28
45	The proteoglycan repertoire of lymphoid cells Bodil Fadnes, Anne Husebekk, Gunbjørg Svineng et al. · Glycoconjugate Journal Book chapterOpen access	10 Jul 2012	27
46	Discovery of Novel Tankyrase Inhibitors through Molecular Docking-Based Virtual Screening and Molecular Dynamics Simulation Studies Vladimir P. Berishvili, Alexander N. Kuimov, Andrew E. Voronkov et al. · Molecules Open access	11 Jul 2020	26
47	Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals Heng Zhou, Laura Mondragón, Wei Xie et al. · Cell Death and Disease Open access	23 Oct 2018	26
48	Rational Design of Conformationally Constrained Cyclopentapeptide Antagonists for C-X-C Chemokine Receptor 4 (CXCR4) Jignesh Mungalpara, Stefanie Thiele, Øystein Eriksen et al. · Journal of Medicinal Chemistry Open access	9 Oct 2012	26
49	The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma Brynjar Mauseth, Ketil André Camilio, Jihua Shi et al. · Molecular Therapy — Oncolytics Open access	20 May 2019	22
50	Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors Ulli Rothweiler, Jonas Eriksson, Wenche Stensen et al. · European Journal of Medicinal Chemistry	24 Feb 2015	22

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.